Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This randomized phase III trial studies cyclophosphamide and doxorubicin hydrochloride
compared with paclitaxel as adjuvant therapy in treating breast cancer in women with 0-3
positive axillary lymph nodes. Giving additional cancer treatment after surgery may help to
lower the risk that the cancer will come back (adjuvant therapy). Drugs used in chemotherapy,
such as cyclophosphamide, doxorubicin hydrochloride, and paclitaxel, work in different ways
to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. It is not yet known whether the standard
adjuvant therapy of cyclophosphamide and doxorubicin hydrochloride is more effective than
paclitaxel in treating women with breast cancer